Samsung Biologics orders hit 3 trillion won in historic milestone
Samsung Biologics has secured five biomanufacturing contracts, bringing the total of its 2023 orders to over 3 trillion won for the first time since its foundation.
Samsung Biologics thrives with big deals, eyes ADC for future
Samsung Biologics continues to thrive in the biopharmaceutical industry, attributing its success to speed, quality, and delivery. The company saw an 18 percent increase in revenue in Q3 and raised its revenue forecast for the year.
Samsung Biologics eyes Barcelona boost at world’s largest pharma show
Samsung Biologics is eyeing new opportunities in Barcelona as it showcases its fifth plant at the CPHI Worldwide 2023 event, the world's largest pharmaceutical trade show.
Samsung Biologics has blowout Q3, revenues hit new high
Samsung Biologics posted a consensus-beating 320 billion won ($240 million) in operating profit in the third quarter, with revenues surpassing 1 trillion won for the first time in its history.
CPHI Worldwide begins in Barcelona with Korean heavyweights
CPHI Worldwide, the largest pharmaceutical trade show, started in Barcelona with major Korean biopharma players in attendance. Over 2,500 companies from 170 countries are exhibiting.
Samsung Biologics signs strategic agreement with Kurma Partners
Samsung Biologics has signed a strategic agreement with Kurma Partners for the development and manufacturing of biologics for Kurma's client companies. The deal will leverage Samsung Biologics' facilities and expertise.
Samsung Biologics banks on antibody drugs as fifth factory progresses
With the 1.98 trillion won ($1.47 billion), 180,000-liter (163,000-quart) Plant 5 slated to begin operation in April 2025, Samsung Biologics is set to secure a contract manufacturing capacity of 784,000 liters a year.
Samsung Biologics raises revenue forecast to $2.65 billion
Samsung Biologics raised its revenue forecast for the year to $2.65 billion, citing new contract manufacturing deals and increased production capabilities.
Samsung Biologics scores $242M Bristol-Myers Squibb deal
Samsung Biologics secures a $242 million contract manufacturing deal with Bristol-Myers Squibb, boosting its total contract wins this year to nearly $2.26 billion.
Samsung's Life Science Fund invests in Korean biotech company
Samsung's Life Science Fund has invested in AimedBio, a Korean biotech firm specializing in antibody-drug conjugates. This is the fund's fourth investment and the first in a domestic company.